True Metrix Blood Glucose Monitors Recalled After Fatal Error Code Flaw
Event summary
- McCune Law Group is investigating injuries and deaths linked to True Metrix blood glucose monitors, following an FDA Class I recall on April 28, 2026.
- The recall involves at least 114 reported injuries and one death due to an 'E-5' error code that fails to distinguish between high blood glucose levels and test strip malfunctions.
- True Metrix devices are distributed under more than 20 store brand names, including Walmart (ReliOn), CVS, Walgreens, and others, affecting millions of diabetic patients.
- The FDA issued an Early Alert in February 2026, escalating to a full recall in April 2026, with Walmart issuing its own recall on May 5, 2026.
The big picture
The True Metrix recall highlights critical gaps in medical device safety, particularly in distinguishing between life-threatening conditions and technical malfunctions. The widespread distribution under store brands exacerbates the issue, as millions of users remain unaware of the recall. This event underscores the need for clearer regulatory guidelines and improved consumer awareness in the medical device sector.
What we're watching
- Regulatory Headwinds
- How the FDA's escalation from Early Alert to Class I recall will impact Trividia Health's regulatory compliance and future product approvals.
- Legal Exposure
- Whether McCune Law Group's investigation will uncover a significantly higher number of affected patients than currently reported.
- Market Impact
- The pace at which retailers like Walmart, CVS, and Walgreens can replace recalled devices and restore consumer trust in their store-branded products.